Objective To analyze the relationship between serum levels of interleukin-2(IL-2),interleukin-6(IL-6),tu-mor necrosis factor-α(TNF-α)and interferon-γ(IFN-γ)and survival in advanced patients with non-small cell lung cancer(NSCLC).Methods A retrospective analysis was performed on 60 patients with advanced NSCLC diagnosed in the Department of Oncology of the First People's Hospital of Fuzhou from October 2021 to September 2022,who were classified as observation group.According to the prognosis 6 months after admission,the patients were divided into survival group(n=41)and death group(n=19).In the same period,66 healthy people were selected as the healthy group.The levels of IL-2,IL-6,TNF-α and IFN-γ within 24 h of admission and after 2 cycles of treatment were recorded,and the levels of IL-2,IL-6,TNF-α and IFN-γ of patients in the survival group and the death group after 2 cycles of treatment were compared.The ROC curve of NSCLC patients'prognosis was drawn with the prognosis of patients as the final variable.Results The levels of IL-6 in healthy group were lower than those in observation group,and the levels of IL-2,TNF-α and IFN-γwere higher than those in observation group,with statistical significances(P＜0.05).Within 24 h after admission,the level of IL-6 in the death group was higher than that in the survival group,and the difference was statistically significant(P＜0.05).After 2 cycles of admission,the levels of IL-2 were lower than those within 24 h,and the levels of IL-6,TNF-α and IFN-γ were higher than those within 24 h,with statistical significance(P＜0.05).After 2 cycles of treatment,IL-6 in survival group was lower than that in death group,and the difference was statistically significant(P＜0.05).ROC results showed that the area under ROC curve,sensitivity,specificity and cut-off value of IL-6 level in the differential diagnosis of NSCLC patients were 0.738,89.47％,65.85％,60.731 pg/ml(P＜0.05).Conclusion IL-6 level can predict the prognosis of advanced NSCLC patients to a certain extent,and can provide guidance for the treatment of clinical NSCLC patients.
维普
万方数据